Supplement to:  Real-World Systemic Treatment Outcomes for Moderate-to-Severe Atopic Dermatitis in Children by Skin Color: 4-Year Results from the observational, international, real-world PEDISTAD Registry

Name: Supplement to: Real-World Systemic Treatment Outcomes for Moderate-to-Severe Atopic Dermatitis in Children by Skin Color: 4-Year Results from the observational, international, real-world PEDISTAD Registry
Creator: Amy Paller
Published: 2026-07-14T03:39:15.148Z
Keywords: Pediatrics, Atopic Dermatitis

Paller, Amy

doi:10.17632/nspv2gstdx.1

Supplement to: Real-World Systemic Treatment Outcomes for Moderate-to-Severe Atopic Dermatitis in Children by Skin Color: 4-Year Results from the observational, international, real-world PEDISTAD Registry

Published: 14 July 2026| Version 1 | DOI: 10.17632/nspv2gstdx.1

Contributor:

Amy Paller

Description

Supplement to: Real-World Systemic Treatment Outcomes for Moderate-to-Severe Atopic Dermatitis in Children by Skin Color: 4-Year Results from the observational, international, real-world PEDISTAD Registry

Files

Funders

Sanofi (United States)
Sanofi (France)
New Jersey, Bridgewater
Regeneron (United States)
New York, Tarrytown

Supplement to: Real-World Systemic Treatment Outcomes for Moderate-to-Severe Atopic Dermatitis in Children by Skin Color: 4-Year Results from the observational, international, real-world PEDISTAD Registry

Description

Files

Categories

Funders

Licence